# Alcon Inc. (ALC)

> Source: Nexqual · https://nexqual.com/ALC · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Alcon Inc. (ALC), nexqual.com/ALC" · informational, not investment advice.

**Price:** USD 70.63 (+4.75% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 67.43 · day 68–70.68 · 52w 61.84–87.64 · market cap $34.1B · NYQ

## Key facts
- 2 of 80 tracked superinvestors hold ALC (13F, Q2 2026): 0 new, 2 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.15 on a 1–5 scale) (27 analysts), mean target USD 82.73 (range 62–103).
- Total return with dividends: 1Y -6.9% vs S&P 500 +14.9%; 5Y -12.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD 0.89, revenue estimate $2.75B.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold ALC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| AKO Capital |  | 15.19% | $652M | Added +3.8% |
| Lee Ainslie | Maverick Capital | 0.02% | $2.2M | Added +159.5% |

## Analysts
Consensus Buy (mean 2.15 on a 1–5 scale), 27 analysts; mean target USD 82.73 (low 62, high 103).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Needham | Reiterated | Buy | $98 |
| 2026-10-12 | BTIG | Target lowered | Buy | $82 → $74 |
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $70 |
| 2026-09-22 | Jefferies | Target lowered | Buy | $95 → $85 |
| 2026-09-15 | Needham | Reiterated | Buy | $98 |
| 2026-08-12 | JP Morgan | Target raised | Neutral | $77.53 → $78.4 |
| 2026-08-12 | Mizuho | Target raised | Outperform | $80 → $85 |
| 2026-08-11 | Needham | Target raised | Buy | $95 → $98 |
| 2026-08-11 | BTIG | Reiterated | Buy | $82 |
| 2026-07-15 | Mizuho | Target lowered | Outperform | $85 → $80 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -6.9% | -12.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -7.0% | -2.6% |
| Volatility (annualized) | 28.4% | 26.9% |
| Max drawdown | -28.5% (Feb 2026→May 2026) | -36.7% (Sep 2024→May 2026) |

## Peers (Medical Instruments & Supplies)
RMD (ResMed Inc.) USD 253.06 +2.79% · WST (West Pharmaceutical Services, I) USD 394.03 +0.14% · MDLN (Medline Inc.) USD 34.88 -1.22% · BDX (Becton, Dickinson and Company) USD 200.42 +3.13% · SOLV (Solventum Corporation) USD 87.45 +0.90% · BAX (Baxter International Inc.) USD 25.65 +3.85%

## More
Full page: https://nexqual.com/ALC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ALC's own 20-F filed 2026-02-24 (https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Lifecore Biomedical | "To ensure sufficient supply, we may determine that we need to provide financing to some suppliers, such as the financing arrangement with Lifecore Biomedical, Inc. we entered into in May 2023, which could increase our fi…" |
| Competitor | Johnson & Johnson (JNJ) | "We primarily compete with Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, Hoya Corporation, Glaukos Corporation and Johnson & Johnson in the surgical market." |
| Competitor | AbbVie (ABBV) | "The vision care market is also highly competitive, and our primary competitors are Johnson & Johnson, Bausch & Lomb Incorporated and The Cooper Companies, Inc. In addition, AbbVie, Inc. (Allergan) is a competitor in ocul…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.89 | $0.89 | +0.4% | $2.75B | 15 |
| Next quarter (ends 2026-12-31) | $0.55 | $0.64 | -13.5% | $2.85B | 6 |
| Current fiscal year (ends 2026-12-31) | $3.50 | $3.47 | +0.9% | $11.09B | 24 |
| Next fiscal year (ends 2027-12-31) | $3.96 | $3.97 | -0.1% | $11.76B | 26 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-10): ±8.7%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 38.7% | ±8.7% |
| 2026-12-18 | 56 | 33.3% | ±10.5% |
| 2027-01-15 | 84 | 30.9% | ±11.9% |
| 2027-02-19 | 119 | 29.8% | ±13.6% |
| 2027-05-21 | 210 | 30.5% | ±18.4% |
| 2027-06-17 | 237 | 30.9% | ±19.7% |